India's Sun Pharma to buy US-listed Organon in about $11.8 billion deal - Reuters

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOT0Y4NFc5aDZpdXQxOFJuZmRGaGF3NE5hSnQ3bEIxNy1WQ2J4LVVRY3JVWHBOMGxiZGRzNlFKOUxReVFvTnBJSkJJRkhkd3laS1BEaEg4Q190X3pSYkp5b3Y4RXo3RlZqVTlZcUdnYVFXMTMzaFpoc3FwckliTkUzeUdNV054cHNKb3dFNjlzX1g2S2JRNHFwRFR4U0dEQm1qb0ZZa3V0T0c2eHA3REQtWkVDZGdXLW5EUHdLdnJ3?oc=5" target="_blank">India's Sun Pharma to buy US-listed Organon in about $11.8 billion deal</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Sun Pharmaceutical Industries will acquire Organon & Co in an all-cash deal, valuing the U.S. drugmaker at about $11.75 billion, including debt.

Sun Pharmaceutical Industries Ltd. agreed to acquire New York-listed women’s health-care company Organon & Co., in what is likely to be one of the biggest India outbound deals in years.

Sun Pharmaceutical Industries has agreed to acquire U.S. drugmaker Organon & Co in an all-cash deal valued at approximately $11.75 billion, including debt.

Sun Pharmaceutical Industries Ltd. has agreed to acquire New York-listed women’s health-care company Organon & Co., expanding its global reach with one of the biggest outbound deals by an Indian company.

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy Organon & Co. in a transaction valuing the New York-listed healthcare company at $11.8 billion.

Sun Pharmaceutical Industries will acquire Organon & Co in an all-cash deal, valuing the US drugmaker at about US$11.75 billion including debt, in one of India’s biggest outbound deals.

Sun Pharmaceutical Industries has agreed to acquire Organon & Co in an all-cash deal valued at approximately $11.75 billion, with Organon shareholders set to receive $14.00 per share.

Sun Pharmaceutical Industries will acquire Organon & Co in an all-cash deal, valuing the US drugmaker at about $11.75 billion including debt, in one of India's biggest outbound deals.